Company Saniona AB Nasdaq Stockholm
Equities
SE0005794617
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100.0
%
| 15 | 100.0 % | 17 | 100.0 % | +10.19% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
51.8
%
| - | - | 9 | 51.8 % | - |
United Kingdom
44.5
%
| - | - | 7 | 44.5 % | - |
Denmark
3.8
%
| - | - | 1 | 3.8 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 10-12-31 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 10-12-31 |
Jørgen Drejer
FOU | Founder | 69 | 10-12-31 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 13-12-31 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 20-04-30 | |
Corporate Officer/Principal | 52 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 10-12-31 |
Director/Board Member | 66 | 14-12-31 | |
Anna Ljung
BRD | Director/Board Member | 44 | 18-01-18 |
Director/Board Member | 58 | 22-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 132,529,086 | 80,887,377 ( 61.03 %) | 0 | 61.03 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |